References
- Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S. Progesterone in
normal and pathological pregnancy. Horm Mol Biol Clin Investig2016;27:35−48.
- Mesen TB, Young SL. Progesterone and the luteal phase: a requisite to
reproduction. Obstet Gynecol Clin North Am 2015;42:135−51.
- Piette P. The history of natural progesterone, the never-ending story.Climacteric 2018;21:308−14.
- Norwitz ER, Caughey AB. Progesterone supplementation and the
prevention of preterm birth. Rev Obstet Gynecol 2011;4:60−72.
- Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr and clinical effects.Endocr Rev 2013;34:171−208.
- Food & Drug Administration. Makena®(hydroxyprogesterone caproate injection) for intramuscular use.
Prescribing information. February 2018. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf
[Accessed 24 August 2020].
- Health Products Regulatory Authority. Duphaston® 10
mg tablets (dydrogesterone). Summary of product characteristics.
December 2016. Available at
https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA2007-005-001_30062017140055.pdf.
[Accessed 24 August 2020].
- Fitzpatrick LA, Good A. Micronized progesterone: clinical indications
and comparison with current treatments. Fertil Steril1999;72:389−97.
- Malik S, Krishnaprasad K. Natural micronized progesterone sustained
release (SR) and luteal phase: role redefined!! J Clin Diagn
Res 2016;10:QE01−4.
- Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is
influenced by vehicle and particle size. Am J Obstet Gynecol1989;161:948−51.
- Kirk PE, Serat S, Burrows LJ, Mott LA, Yeo K-TJ, Fitzmaurice T, et al.
A pharmacokinetic study of natural micronized progesterone extended
release tablets. Available at:
https://pharmacysolutionsonline.com/progesterone-even-release-tablets.php.
[Accessed 24 August 2020].
- Malhotra J, Krishnaprasad K. Open-label, prospective, investigator
initiated study to assess the clinical role of oral natural or
synthetic progesterone during stimulated IUI cycles for unexplained
infertility. J Clin Diagn Res 2016;10:QC08−10.
- Vaisbuch E, de Ziegler D, Leong M, Weissman A, Shoham Z. Luteal-phase
support in assisted reproduction treatment: real-life practices
reported worldwide by an updated website-based survey. Reprod
Biomed Online 2014;28:330−5.
- van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M.
Luteal phase support for assisted reproduction cycles. Cochrane
Database Syst Rev 2015;7:CD009154.
- Colwell KA, Tummon IS. Elevation of serum progesterone with oral
micronized progesterone after in vitro fertilization. A randomized,
controlled trial. J Reprod Med 1991;36:170−2.
- Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, et al.
Luteal support after in-vitro fertilization: Crinone 8%, a sustained
release vaginal progesterone gel, versus Utrogestan, an oral
micronized progesterone. Hum Reprod 1996;11:2085−9.
- Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El
R. Luteal support with micronized progesterone following in-vitro
fertilization using a down-regulation protocol with
gonadotrophin-releasing hormone agonist: a comparative study between
vaginal and oral administration. Hum Reprod 1999;14:1944−8.
- Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA.
Oral versus intramuscular progesterone for in vitro fertilization: a
prospective randomized study. Fertil Steril 1999;71:614−8.
- Tomic V, Tomic J, Klaic DZ. Oral micronized progesterone combined with
vaginal progesterone gel for luteal support. Gynecol Endocrinol2011;27:1010−3.
- Gopinath PM, Desai RR. Open-label observational study to determine the
success rate of first cycle intrauterine insemination (IUI) involving
luteal phase support with oral natural or synthetic progesterone.Int J Med Res Health Sci 2014;3:933−6.
- Bahadur G, Homburg R, Al-Habib A. A new dawn for intrauterine
insemination: efficient and prudent practice will benefit patients,
the fertility industry and the healthcare bodies. J Ob Gyn
India 2017;67:79−85.
- Güven D, Batıoğlu A, Sari S, Bakay K. The impact of progesterone
supplementation on pregnancy rates after intrauterine insemination in
patients developing a single follicle. Hum Fertil (Camb)2016;19:111−3.
- Chi HB, Xin LL, Li R, Li NN. [Study of the effects of three luteal
phase supporting strategies on clinical outcomes of intrauterine
insemination]. Zhonghua Yi Xue Za Zhi 2016;96:1830−3.
Chinese.
- Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing
miscarriage in women with recurrent miscarriage of unclear etiology.Cochrane Database Syst Rev 2018;10:CD003511.
- Marinov B, Petkova S, Dukovski A, Georgiev G, Garnizov T, Manchev V,
et al. [Utrogestan and high risk pregnancy]. Akush Ginekol
(Sofiia) 2004;43(5):22−4. Bulgarian.
- Turgal M, Aydin E, Ozyuncu O. Effect of micronized progesterone on
fetal-placental volume in first-trimester threatened abortion. J
Clin Ultrasound 2017;45:14−9.
- Siew JYS, Allen JC, Hui CYY, Ku CW, Malhotra R, Østbye T, et al. The
randomised controlled trial of micronised progesterone and
dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet
Gynecol Reprod Biol 2018;228:319−24.
- Jarde A, Lutsiv O, Park CK, Beyene J, Dodd JM, Barrett J, et al.
Effectiveness of progesterone, cerclage and pessary for preventing
preterm birth in singleton pregnancies: a systematic review and
network meta-analysis. BJOG 2017;124:1176−89.
- Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal
administration of progesterone for preventing preterm birth in women
considered to be at risk of preterm birth. Cochrane Database
Syst Rev 2013;7:CD004947.
- Rai P, Rajaram S, Goel N, Gopalakrishnan RA, Agarwal R, Mehta S. Oral
micronized progesterone for prevention of preterm birth. Int J
Gynaecol Obstet 2009;104:40−3.
- Ashoush S, El-Kady O, Al-Hawwary G, et al. The value of oral
micronized progesterone in the prevention of recurrent spontaneous
preterm birth: a randomized controlled trial. Acta Obstet
Gynecol Scand 2017;96:1460−6.
- Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A
randomized trial of micronized progesterone for the prevention of
recurrent preterm birth. Am J Perinatol 2011;28:377−81.
- Boelig RC, Della Corte L, Ashoush S, Othman A. Oral progesterone for
the prevention of recurrent preterm birth: systematic review and
metaanalysis. Am J Obstet Gynecol MFM 2019;1:50−62.
- Tariq M, Naeem F, Rasheed S. Efficacy of oral progesterone in preterm
births at a tertiary care hospital. J Med Physiol Biophysics2017;37:44−8.
- Natu N, Sonker S, Chandwaskar N, Agrawal S. Role of micronized
progesterone versus vaginal progesterone for prevention of preterm
labour. Int J Repro Contracep Obs Gyn 2017;6:1797−9.
- Noblot G, Audra P, Dargent D, Faguer B, Mellier G. The use of
micronized progesterone in the treatment of menace of preterm
delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203−9.
- Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MMA. Maintenance
tocolysis with oral micronized progesterone for prevention of preterm
birth after arrested preterm labor. Int J Gynaecol Obstet2014;126:60−3.
- Prabhat P, Krishnaprasad K. A drug utilization surveillance study to
assess the clinical utility and safety of oral natural micronized
progesterone SR in high risk pregnancies: NAP-DELAY study. J
Clin Diag Res 2018;12:QC04−6.
- Purandare AC, Hajare A, Krishnaprasad K, Bhargava A. Prescription
event monitoring study to assess the safety profile of oral natural
micronized progesterone sustained release in India. Int J Med
Res Health Sci 2014;3:975−6.
- Zaqout M, Aslem E, Abuqamar O, Abughazza O, Panzer J, De Wolf D.
Association between oral intake of dydrogesterone during early
pregnancy and congenital heart disease: a case-control study.Lancet 2017;390(S*):Abstract.
- Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C,
et al. Dydrogesterone: pharmacological profile and mechanism of action
as luteal phase support in assisted reproduction. Reprod Biomed
Online 2019;38:249−59.
- Freeman EW, Weinstock L, Rickels K, Sondheimer SJ, Coutifaris C. A
placebo-controlled study of effects of oral progesterone on
performance and mood. Br J Clin Pharmacol 1992;33:293−8.
- Ottosson UB, Johansson BG, von Schoultz B. Subfractions of
high-density lipoprotein cholesterol during estrogen replacement
therapy: a comparison between progestogens and natural progesterone.Am J Obstet Gynecol 1985;151:746−50.
- Darj E, Axelsson O, Carlström K, Nilsson S, von Schoultz B. Liver
metabolism during treatment with estradiol and natural progesterone.Gynecol Endocrinol 1993;7:111−4.
- Frishman GN, Klock SC, Luciano AA, Nulsen JC. Efficacy of oral
micronized progesterone in the treatment of luteal phase defects.J Reprod Med 1995;40:521−4.